Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Revenue Recognized by Revenue Source

The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2023 and 2022 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Pharmaceutical Development Segment
License Agreement	$	10	$	16	$	10	$	132
Pharmaceutical Development and other		173		98		291		698
Total contract revenue	$	183	$	114	$	301	$	830

The Company’s contract liabilities are presented as deferred revenues and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):

The Company’s contract liabilities are presented as deferred revenues and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):

	June 30, 2023		December 31, 2022
Pharmaceutical Development Segment
Deferred revenue	$	30	$	33
Total contract liabilities	$	30	$	33